Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing new treatments for blood coagulation disorders. The company aims to improve the lives of patients in the United States of America and Denmark. Its primary product, HMB-001, is a bispecific antibody currently undergoing Phase 1/2 clinical development for the preventative treatment of Glanzmann thrombasthenia. HMB-001 is also in Phase 2 clinical development for the preventative treatment of Factor VII deficiency. Another clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development. HMB-002 is designed for subcutaneous preventative treatment of Von Willebrand disease. In addition to its clinical programs, Hemab Therapeutics Holdings, Inc. is advancing several assets in preclinical and discovery stages. The company was established in 2020 and is headquartered in Cambridge, Massachusetts.